All Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Jan. 5, 2023 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel,…dantetzlJanuary 5, 2023
AllMayflower BioVentures First startup blooms from Mayo Clinic cell and gene therapy accelerator with $750M Cellectis partnership Seeds from Mayo Clinic’s cell and gene therapy accelerator Mayflower Bioventures have taken flight in…dantetzlJanuary 3, 2023
AllMayflower BioVentures Mayo Clinic Joins With Industry Groups to Launch Biotech Accelerator Mayo Clinic has joined with two industry partners to start an accelerator for cell- and…dantetzlAugust 31, 2022
AllMayflower BioVentures Mayo Clinic, Hibiscus BioVentures and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator ROCHESTER, Minn. and ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch…dantetzlAugust 31, 2022
3DBio TherapeuticsAll 3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial - AuriNovo™ an investigational, 3D-bioprinted implant was created using a proprietary process leveraging the patient’s…dantetzlJune 2, 2022
All Innoforce and Hibiscus BioVentures Announce Strategic Partnership to Enable Development of Advanced Therapies - Partnership enables Hibiscus BioTechnology Studio Companies access to Innoforce's advanced therapies drug development capabilities…dantetzlMarch 16, 2022